1. Ahmad R, Ahsan H. Dual autoimmune diseases: Rheumatoid arthritis with systemic lupus erythematosus and Type 1 diabetes mellitus with multiple sclerosis. Rheumatol Autoimmun. 2022;2(3):120-8.
2. Hosseinzadeh A, Baneshi MR, Sedighi B, Kermanchi J, Haghdoost AA. Incidence of multiple sclerosis in Iran: A nationwide, population-based study. Public Health. 2019;175:138-44.
3. Yamout BI, Assaad W, Tamim H, Mrabet S, Goueider R. Epidemiology and phenotypes of multiple sclerosis in the Middle East North Africa (MENA) region. Mult Scler J Exp Transl Clin. 2020;6(1):2055217319841881.
4. Eskandarieh S, Molazadeh N, Moghadasi AN, Azimi AR, Sahraian MA. The prevalence, incidence, and familial recurrence of multiple sclerosis in Tehran, Iran. Mult Scler Relat Disord. 2018;25:143.
5. Legroux L, Arbour N. Multiple sclerosis and T lymphocytes: An entangled story. J Neuroimmune Pharmacol. 2015;10(4):528-46.
6. Greenfield AL, Hauser SL. B-cell therapy for multiple sclerosis: Entering an era. Ann Neurol. 2018;83(1):13-26.
7. Marabita F, Almgren M, Sjöholm LK, Kular L, Liu Y, James T, et al. Smoking induces DNA methylation changes in multiple sclerosis patients with exposure-response relationship. Sci Rep. 2017;7(1):14589.
8. Pourostadi M, Sattarpour S, Poor BM, Asgharzadeh M, Kafil HS, Farhoudi M, et al. Vitamin D receptor gene polymorphism and the risk of multiple sclerosis in the Azeri population of Iran. Endocr Metab Immune Disord Drug Targets. 2021;21(7):1306-11.
9. Asgharzadeh M, Sanajoo D, Mahdavi Poor B, Samadi Kafil H, Gholizadeh P, Rashedi J. Interleukin-10 promoter and the CCR5 polymorphisms in Iranian Azari population with multiple sclerosis. Iran J Immunol. 2021;18(3):241-8.
10. Asgharzadeh V, Rezaei SA, Poor BM, Asgharzadeh M, Nobari HJ, Taghinejad Z, et al. The association between diet and multiple sclerosis. Endocr Metab Immune Disord Drug Targets. 2024;24(8):909-17.
11. Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle, and environmental risk factors for multiple sclerosis. Nat Rev Neurol. 2017;13(1):25-36.
12. Mihailova S, Ivanova M, Mihaylova A, Quin L, Mikova O, Naumova E. Pro- and anti-inflammatory cytokine gene polymorphism profiles in Bulgarian multiple sclerosis patients. J Neuroimmunol. 2005;168(1-2):138-43.
13. Laxminarayana D. Molecular insights into onset of autoimmunity in SARS-CoV-2 infected patients. Rheumatol Autoimmun. 2022;2(4):198-202.
14. Bahar M, Ashtari F, Aghaei M, Akbari M, Salari M, Ghalamkari S. Mycoplasma pneumonia seropositivity in Iranian patients with relapsing-remitting multiple sclerosis: A randomized case-control study. J Pak Med Assoc. 2012;62(3 Suppl 2):S6-8.
15. Kaskow BJ, Baecher-Allan C. Effector T cells in multiple sclerosis. Cold Spring Harb Perspect Med. 2018;8(4):a029025.
16. Libbey JE, Cusick MF, Fujinami RS. Role of pathogens in multiple sclerosis. Int Rev Immunol. 2014;33(4):266-83.
17. Ha EK, Kim JH, Cha HR, Han BE, Shin YH, Baek HS, et al. Investigating the occurrence of autoimmune diseases among children and adolescents hospitalized for Mycoplasma pneumoniae infections. Front Immunol. 2023;14:1165586.
18. Maida E. Immunological reactions against Mycoplasma pneumoniae in multiple sclerosis: Preliminary findings. J Neurol. 1983;229(2):103-11.
19. Abrahamyan S, Eberspächer B, Hoshi MM, Aly L, Luessi F, Groppa S, et al. Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis. J Neurol Neurosurg Psychiatry. 2020;91(7):681-6.
20. He R, Du Y, Wang C. Epstein-Barr virus infection: The leading cause of multiple sclerosis. Signal Transduct Target Ther. 2022;7(1):239.
21. Kawada JI, Ito Y, Ohshima K, Yamada M, Kataoka S, Muramatsu H, et al. Updated guidelines for chronic active Epstein-Barr virus disease. Int J Hematol. 2023;118(5):568-76.
22. Soldan SS, Lieberman PM. Epstein-Barr virus and multiple sclerosis. Nat Rev Microbiol. 2023;21(1):51-64.
23. Khalili N, Khalili N, Nickhah A, Khalili B. Seroprevalence of anti-Toxocara antibody among multiple sclerosis patients: A case-control study. J Parasit Dis. 2020;44(1):145-50.
24. Nicoletti A, Cicero CE, Giuliano L, Todaro V, Lo Fermo S, Chisari C, et al. Toxoplasma gondii and multiple sclerosis: A population-based case-control study. Sci Rep. 2020;10(1):18855.
25. Correale J, Farez MF. The impact of environmental infections (parasites) on MS activity. Mult Scler. 2011;17(10):1162-9.
26. Sayama A, Okamoto M, Tamaki R, Saito-Obata M, Saito M, Kamigaki T, et al. Comparison of rhinovirus A-, B-, and C-associated respiratory tract illness severity based on the 5'-untranslated region among children younger than 5 years. Open Forum Infect Dis. 2022;9(10):ofac387.
27. Kriesel JD, Sibley WA. The case for rhinoviruses in the pathogenesis of multiple sclerosis. Mult Scler. 2005;11(1):1-4.
28. Nicolson GL, Haier J. Role of chronic bacterial and viral infections in neurodegenerative, neurobehavioral, psychiatric, autoimmune, and fatiguing illnesses: Part 1. Br J Med Pract. 2009;2(4):20-8
29. Cossu D, Yokoyama K, Hattori N. Bacteria-host interactions in multiple sclerosis. Front Microbiol. 2018;9:2966.
30. Fainardi E, Castellazzi M, Seraceni S, Granieri E, Contini C. Under the microscope: Focus on Chlamydia pneumoniae infection and multiple sclerosis. Curr Neurovasc Res. 2008;5(1):60-70.
31. Sakai RE, Feller DJ, Galetta KM, Galetta SL, Balcer LJ. Vision in multiple sclerosis: The story, structure-function correlations, and models for neuroprotection. J Neuroophthalmol. 2011;31(4):362-73.
32. Sewell DL, Reinke EK, Co DO, Hogan LH, Fritz RB, Sandor M, et al. Infection with Mycobacterium bovis BCG diverts traffic of myelin oligodendroglial glycoprotein autoantigen-specific T cells away from the central nervous system and ameliorates experimental autoimmune encephalomyelitis. Clin Diagn Lab Immunol. 2003;10(4):564-72.
33. Jaruvongvanich V, Sanguankeo A, Jaruvongvanich S, Upala S. Association between Helicobacter pylori infection and multiple sclerosis: A systematic review and meta-analysis. Mult Scler Relat Disord. 2016;7:92-7.